U.S. AI in Pharmaceutical Market to Reach USD 15.10 Billion and Europe USD 12.60 Billion by 2035 as Generative AI, Adaptive Trials, and Regulatory Endorsement Drive Growth.

Austin, United States, Sept. 07, 2026 (GLOBE NEWSWIRE) -- AI in Pharmaceutical Market Size & Growth Analysis:

According to SNS Insider, The AI in Pharmaceutical Market was valued at USD 3.07 Billion in 2025 and is expected to reach USD 48.43 Billion by 2035, growing at a CAGR of 31.76% from 2026 to 2035. Rapid growth is being fueled by increased venture capital, favorable regulations, and protein folding model developments as investments are moving from changing chemicals in drug development to data science. Adaptive trials are already reducing the time taken for patient recruitment by about 40%, pharmacovigilance software that mines electronic health records assists companies in meeting post-market requirements, and AI-enabled wearables are being employed to remotely track patients with life-threatening conditions.

The U.S. FDA qualified AIM-NASH in December 2025 as its first machine-learning biomarker, marking a shift from cautious observation to active endorsement of algorithmic drug-development tools and setting a regulatory precedent that continues encouraging broader industry investment in AI-driven development platforms.


Download the AI in Pharmaceutical Market Sample Report: https://www.snsinsider.com/sample-request/7678

AI in Pharmaceutical Market Key Highlights

  • Market size, 2025: USD 3.07 Billion
  • Market size, 2026E: USD 4.05 Billion
  • Market forecast, 2035: USD 48.43 Billion
  • CAGR: 31.76% from 2026 to 2035
  • Largest region: North America
  • Fastest-growing region: Asia Pacific
  • Largest technology: Machine Learning, approximately 38.21% share in 2025
  • Fastest-growing technology: Generative AI, approximately 42.31% CAGR
  • Largest offering: Software Platforms, approximately 45.32% share in 2025
  • Fastest-growing offering: AI-as-a-Service, approximately 43.78% CAGR
  • Largest application: Drug Discovery & Pre-Clinical Development, approximately 34.42% share in 2025
  • Fastest-growing application: Pharmacovigilance & Safety Monitoring, approximately 43.65% CAGR
  • Largest deployment mode: Cloud, approximately 67.72% share in 2025
  • Fastest-growing deployment mode: On-Premises/Hybrid, approximately 42.76% CAGR

Market Relevance

Artificial intelligence has taken the stage in pharmaceutical discovery, owing to the venture capital backing, regulatory approval, and advancements in generative protein-folding modeling that are now diverting R&D efforts from chemical means to data-driven ones. Algorithms designed for adaptive trials have already shrunk patient enrollment periods by nearly 40%.

AI in Pharmaceutical Market Overview

The market includes the technologies of machine learning and generative AI as software platforms and AI-as-a-service solutions, which are used in cloud and on-premises/hybrid architecture in drug discovery, pre-clinical testing, and pharmacovigilance use cases. Machine learning continues to be a key component of the existing solutions for drug discovery, trials optimization, and safety monitoring, whereas generative AI is changing the approach of discovery through protein folding models. Cloud implementation helps to address computing requirements of AI, whereas hybrid solutions are popular among companies with proprietary data.

Strategic Market Outlook

Growth potential exists in the expansion of AI-as-a-Service and precision medicine. Increasing interest in flexible consumption-based AI is creating an opening for those able to cater to smaller biotech companies and start-ups that do not have enough incentive to build their own in-house infrastructure, while increasing funding for precision medicine is generating demand for AI technology that could lower the costs of drugs and reduce clinical trial failures.

Quality of data and need for algorithm validation is a significant barrier. High-quality and comprehensive datasets are needed in order to achieve reliable results from AI algorithms and these datasets are still scattered across various pharmaceutical companies, while increased regulatory validation requirements increase the deployment costs despite increasingly favorable regulatory climate.

AI in Pharmaceutical Market Regional Analysis

North America dominated the global market share in 2025 owing to the existence of major pharmaceutical companies, superior healthcare infrastructure, and investment in AI-first pharmaceutical pipelines. The United States constituted about 86.90% of the North American revenue due to the presence of leading pharmaceutical and AI technology firms, whereas Canada accounted for a smaller but increasing market share through its biotech research industry.

The market size of the U.S. AI in Pharmaceutical market stood at USD 0.94 Billion in 2025 and it is anticipated to touch USD 15.10 Billion by 2035 at a CAGR of 32.00% from 2026 to 2035. In 2025, Isomorphic Labs, established by Alphabet (Google DeepMind), received an investment of USD 1 billion, indicating that the market is confident in AI-first pharma pipelines than chemistry-based discovery.

The Europe AI in Pharmaceutical Market had about 28% of the total market in 2025, amounting to USD 0.86 Billion and is forecasted to be valued at USD 12.60 Billion by 2035, recording a CAGR of 30.80% during the period of 2026 to 2035. The market growth can be attributed to the presence of extensive pharmaceutical manufacturing industry and increasing investments in biotechnology research. Germany had a share of 27.60% of the total revenue in Europe in 2025 due to the prevalence of pharmaceutical industries incorporating AI in the drug development process in the country, whereas France, the U.K., and Switzerland have followed the same pattern of growth.

In terms of the fastest growing region, the Asia-Pacific region dominated with the rapid growth of biotechnology research and increased healthcare investments in the major economies of the region. In 2025, China had a share of 37.40% of the regional revenue due to the extensive investments made by the government of the country in domestic AI and biotechnology infrastructure.

Middle East & Africa: The UAE accounted for approximately 27.80% of regional revenue in 2025, supported by technology diversification policies and rising government funding for health innovation across the Gulf countries.

Latin America: Brazil led regional revenue at approximately 37.20% in 2025, supported by growing pharmaceutical research investment.

Buy the AI in Pharmaceutical Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/7678

AI in Pharmaceutical Market Segment Analysis

By Technology: Market share for Machine Learning in 2025 stood at about 38.21%, driven largely by the proven capabilities of existing algorithms that are used in almost all drug discovery, trials optimization, and safety monitoring. Generative AI is the segment that is seeing the fastest growth rate, at about 42.31% CAGR, driven by developments in protein folding.

By Offering: The Software Platforms captured nearly 45.32% of the market share during 2025 due to the incorporation of AI platforms within the R&D process through licenses. AI-as-a-Service is the most rapid growing segment due to 43.78% of CAGR as small biotech companies prefer consumption-based services.

By Application: The Drug Discovery & Pre-clinical Development application held a 34.42% market share in 2025 due to high Phase I success rates in AI-discovered molecules compared to conventional methods. The Pharmacovigilance & Safety Monitoring application is expected to witness the highest growth rate of around 43.65% CAGR owing to increasing regulatory focus on safety monitoring.

By Deployment Mode: Cloud was estimated to have a 67.72% share of the market in 2025, where firms opt for computing resources that can scale without investing heavily in infrastructure internally. On-Premises/Hybrid is the most rapidly growing model, having a 42.76% CAGR, since firms dealing with sensitive research data prefer models that combine the two.

AI in Pharmaceutical Market Key Trends

  • Venture funding redirecting R&D capital toward data-centric AI platforms rather than incremental chemistry approaches
  • Adaptive-trial algorithms cutting clinical enrollment timelines by roughly forty percent
  • Pharmacovigilance engines mining electronic health records in near real time to meet surveillance mandates
  • Generative protein-folding models advancing drug discovery capability beyond traditional chemistry approaches
  • Regulatory bodies shifting from cautious observation toward active endorsement of algorithmic drug-development tools

Competitive Landscape

The AI in Pharmaceutical Market includes established pharmaceutical companies, computing infrastructure providers, and AI-first drug discovery startups, with competition centred on generative protein-folding models and computational infrastructure.

In 2025, Xaira Therapeutics secured a billion-dollar funding round, reflecting strong capital market confidence in AI-first pharmaceutical pipelines. NVIDIA Corporation continued expanding its computing infrastructure partnerships with pharmaceutical companies, supporting the processing power required for generative protein-folding models. Recursion Pharmaceuticals continued advancing its AI-driven drug discovery platform following its merger integration, strengthening its position applying machine learning to identify novel therapeutic candidates.

Major key players include

  • AstraZeneca plc
  • Atomwise Inc.
  • Bayer AG
  • Cloud Pharmaceuticals Inc.
  • GNS Healthcare, Inc.
  • IBM Corporation
  • Merck & Co., Inc.
  • Microsoft Corporation
  • Novartis AG
  • NVIDIA Corporation
  • Pfizer Inc.
  • Recursion Pharmaceuticals, Inc.
  • XtalPi Inc.
  • Isomorphic Labs Limited
  • Insitro, Inc.
  • Insilico Medicine
  • Schrödinger, Inc.
  • Xaira Therapeutics, Inc.
  • BenevolentAI Ltd.
  • Tempus AI, Inc.

Explore the Complete AI in Pharmaceutical Market Report: https://www.snsinsider.com/reports/artificial-intelligence-in-pharmaceutical-market-7678

CONTACT: About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315-961-9094 (US)
Email: info@snsinsider.com